healthcareinputs

[healthcareinputs]

Dialysis Devices Market Growth to Remain Steady during 2018 – 2026 at a CAGR of 5.65%

The Dialysis Devices Market was valued at US $17.99 billion in the year 2018 and is estimated to reach US $27.88 billion by 2026, at a CAGR of 5.65%    

 Dialysis is the treatment method for the patients with end-stage renal disease (ESRD) or kidney injury until they get kidney transplant and, for lifetime in case of transplant kidney rejection and lack of kidney donors.

 According to the World Health Organization (WHO), the geriatric population is expected to rise from 900 million in 2015 to around 2 billion by the year 2050 and by 2020, the geriatric population will outnumber the population of children below 5 years of age. The geriatric population is more prone to kidney diseases. Thus, dialysis procedures will rise in the forthcoming years fueling market growth. The Asia Pacific is the region which has immense potential for the growth of dialysis devices market during the forecast period owing to its population growth, increasing per capita income, advancement in health care infrastructure, cost-effectiveness in the surgical procedures, supportive government activities in these emerging countries, Rising cases of hypertension, diabetes, and kidney failure are anticipated to be the major factors driving the Dialysis Devices Market.  

The key drivers for the Dialysis Devices market are the increasing number of ESRD patients, growing number of patients suffering from hypertension and diabetes, rise in aging population, rising adoption of dialysis procedures over renal transplants, technological advancements are driving the market growth, Improvement of healthcare infrastructure in developing countries. The key market restraint is high treatment cost, risk and complications associated with dialysis such as anemia and infection, low blood pressure, product recalls.

Optima Insights provides the latest update on the industry trends, products & pipeline analysis with country, regional and global revenue forecast till the year 2026. The analysis of the market is segmented into Dialysis Devices Market Based on Product (Hemodialysis Devices, Peritoneal Dialysis Devices, Continuous Renal Replacement Therapy (CRRT) Systems, Consumables); End-User (Hospitals, Clinics, Ambulatory surgical centers, Home care settings); Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

 Request for Sample Pages @ https://www.optimainsights.org/sample-request/201-dialysis-devices-market

 Major companies which develop dialysis devices include Fresenius Medical Care AG & Co. KGaA, Medtronic Plc, Becton, Dickinson and Company, Nikkiso Co. Ltd, Asahi Kasei Corporation, B. Braun Avitum AG, Baxter International. According to clinicaltrials.gov, there are more than 700 active clinical trials for the dialysis devices

 Research Scope

·         Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.

       •   Provides a Comparative Analysis of Key Marketed and Pipeline Products.

       •   Provides Key Information on Players involved.

·         Provides a Complete Overview of Market Segments and the Regional Outlook.

·         Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.

 The Report Provides Key Insights on

·         History of the Dialysis Devices Market, 2015 to 2017

·         Forecast of the Dialysis Devices Market Growth till the year 2026

·         The key market drivers, restraints, challenges, future opportunities and the market dynamics      driving the Dialysis Devices Market

·         Analysis of potential growth segments which will drive the market

·         Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market

·         Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics

Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/201-dialysis-devices-market

             About Us

 Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.

 Contact

             Optima Insights

Mr. Chucks G

             +91 966 6620 365 (Asia) | +1 424 2554 365 (US)

             Email: sales@optimainsights.org

             https://www.optimainsights.org

[healthcareinputs]

COPD Drugs Market: Future Demand and Growth Analysis

The Chronic Obstructive Pulmonary Disease (COPD) was valued at US $10.78 billion in the year 2018 and is estimated to reach US $14.27 billion by 2026, at a CAGR of 3.57%.

Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung disease that causes airflow obstruction and breathing difficulties. COPD is characterized by emphysema, chronic bronchitis, and refractory (non-reversible) asthma. Further, COPD symptoms include frequent coughing, increased breathlessness, wheezing and tightness in the chest.

The class of drugs for the treatment of COPD includes bronchodilators, leukotriene antagonists, mast cell stabilizers and immunosuppressants. The bronchodilator drugs for the treatment of COPD are Long-Acting β2 Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA), Short-Acting β2 Agonists (SABA), Short-Acting Muscarinic Antagonists (SAMA), Phosphodiesterase Inhibitors, LABA/LAMA Fixed-Dose Combinations, and SABA/SAMA Fixed-Dose Combination.

According to National Health Interview Survey Cape Town, South Africa, has the highest prevalence, affecting 22.2% of men and 16.7% of women and Germany has the lowest prevalence, 8.6% for men and 3.2%. There were around 251 million cases of COPD reported globally by WHO. Tobacco smoking is a major risk factor for COPD and approximately 20% of smokers develop the disease and about 15–20 % of COPD cases are due to occupational exposures to pollutants at the workplace. COPD is currently the fifth-leading cause of mortality worldwide. The Third National Health and Nutrition Examination Survey showed a prevalence of COPD in adults of 6.8 percent in the USA. The prevalence of COPD in Africa varies between 4% and 25% across the countries.

The major challenge was to create awareness about smoking effects and conduct De-addiction programs, counseling along with a therapeutic approach for COPD affected smokers. Currently, more than 20 pipeline drugs are under development which is expected to hit the market creating positive growth impact in the forecast period. North American & the European regions are the market leaders due to the high prevalence of COPD patients as well as the presence of major companies. However, due to a surge in the industrial activities in the Asian Pacific region, especially in China, India, Vietnam, Bangladesh, etc. are decreasing the air quality to a greater level. These regions are expected to contribute to the overall growth of the COPD population and the market growth is expected to a greater extent in the forecast period.

The key driver for the COPD market is the increasing prevalence of respiratory diseases owing to the increasing geriatric population and smoking population. Increased automotive, industrial exhaust gases are degrading air quality and have led to the increased incidence of asthma due to immense pollution, especially in the low-income population in the emerging economies. The key market restraint is high treatment cost, the growing portfolio of generic drugs, and patent expiration of key blockbuster drugs.

Major companies which develop drugs for Chronic Obstructive Pulmonary Disease (COPD) include AstraZeneca, F. Hoffmann-La Roche, Novartis AG, Merck & Co, GlaxoSmithKline Plc, Boehringer Ingelheim Gmbh, Nycomed, Abbott Laboratories, Cipla, Dr. Reddy’s Laboratories, Glenmark, Mylan, Pfizer, Ranbaxy, Sunovion, and Vectura. According to clinicaltrials.gov, there are more than 350 ongoing interventional clinical trials for the treatment of Chronic Obstructive Pulmonary Disease (COPD) at present.

Recent Updates

·         In March 2019, Novartis AG launched Ultibro Breezhaler and Seebri Breezhaler in China, for the treatment of chronic obstructive pulmonary disease.

·         In April 2019, Cipla launched Niveoli in India, beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults suffering from obstructive airway diseases (OAD) such as asthma and chronic obstructive pulmonary disorder (COPD).

·         In April 2019, Circassia announced FDA approval of Duaklir®, aclidinium bromide/formoterol fumarate combination maintenance treatment for COPD

Chronic Obstructive Pulmonary Disease (COPD) Market Based on Treatment Class (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn):

·         Bronchodilators

·         Leukotriene antagonists

·         Mast cell stabilizers

·         Immunosuppressants

Chronic Obstructive Pulmonary Disease (COPD) Market Based on Distribution Channel (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn):

·         Hospital Pharmacies

·         Retail Pharmacies

·         Online Pharmacies

 Chronic Obstructive Pulmonary Disease (COPD) Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

·         North America

·         Europe

·         APAC

·         LAMEA

·         Research Scope

 Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments of Chronic Obstructive Pulmonary Disease (COPD) Drugs Market.

Provides a Comparative Analysis of Key Marketed and Pipeline Products.

Provides Key Information on Players involved in Chronic Obstructive Pulmonary Disease (COPD) Drugs Market.

Provides a Complete Overview of Market Segments and the Regional Outlook of Chronic Obstructive Pulmonary Disease (COPD) Drugs Market.

Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.

 Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/167-chronic-obstructive-pulmonary-disease-drugs-market

 About Us

 Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.

 Contact

Optima Insights

 Mr Chucks G

+91 966 6620 365 (Asia) | +1 424 2554 365 (US)

Email: info@optimainsights.org

https://www.optimainsights.org

[healthcareinputs]

Migraine Drugs Market trends and Growth Opportunities

The Global Migraine Drug Market was valued at US$3.9 billion in the year 2018 and is expected to reach US$8.2 billion by 2026, at a CAGR of 9.73%.

Migraine Drugs are a group of medication that is given for the relief of symptoms associated with migraine pain. Around 18 to 19 % of the global populace complain of frequent chronic headaches. In the UK alone, the reported cases of migraine headaches each day extends to about 190,000, which is considered very high. The incidence of migraine peaks between 15 and 24 years of age, wherein the prevalence is high among individuals aged between 35 and 45 years. Out of this, women are more vulnerable to acquire migraine headaches in comparison to the male population.

As per the Migraine Association of Ireland, the proportion of female to male migraineurs was observed to be 3:1. This increased proportion is due to the variations in the estrogen levels during menstruation. This rising instance of migraine among the female populace is set to drive the development of a migraine drug market in the region.

Rise in the female population, the introduction of calcitonin gene-related & peptide-based therapies, a surge in awareness among the patients related to prevention & treatment and improved uptake of novel drug classes are boosting the migraine drugs market. Also, the FDA has approved several drugs such as Aimovig for the prevention of chronic migraines, which may provide promising opportunities for the progress of the migraine drug market. However, side-effects and risks that are associated with these new-generation drugs may hamper the market growth.

Allergan's Botox was in a solid focused position in the preventive migraine market. As the main endorsed medication, Botox significantly covers around 60.0% of the market share. However, Botox is expected to face rivalry from launch of Amgen/Novartis' Aimovig which engrossed around US$ 59 million in 2019 Q1 sales and which is expected to reach more than US$ 1billion at the end of 2022and other exceptionally viable CGRP-based treatments, which targets both chronic and episodic migraine, unlike Botox, which is only approved for the chronic variant of the condition.

Companies such as Pfizer Inc., GlaxoSmithKline plc, Allergan plc, Amgen Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Biohaven Pharmaceutical, Johnson and Johnson, and Bausch Health Companies Inc, etc., are also keen on launching their migraine drugs depending upon the competition, pricing of the competitors, etc.

Optima Insights had classified the migraine drug market based on the route of administration, therapeutic class, treatment class, and regions. The oral segment engrossed maximum revenue when compared to the injectable segment. Especially, drugs such as oral diclofenac potassium 50 mg are successful in treating the intense headache.

The CGRP antagonists and antibodies are said to dominate the overall market share with maximum revenue generation in the upcoming years. Because of R&D activities, for example, nitrous oxide inhibition, corticotrophin receptor antagonism, and CGRP-based receptor and ligand inhibition. Approval of CGRP monoclonal antibodies is one of the key advancements in the preventive market. The CGRP inhibitor propelled in Europe in July 2018 and North America during May 2018 and has received a positive reaction from patients and healthcare providers.

Eli Lilly's Emgality (galcanezumab) also received FDA endorsement in October 2018. In September 2018, Teva's Ajovy (fremanezumab) turned into the second CGRP treatment to be approved by the FDA for headache prevention. Ajovy is the sole CGRP monoclonal therapeutic acting agent that gives patients quarterly and monthly dosing alternatives.

The abortive drugs are utilized more in controlling the severity of migraine headaches and also to reduce the frequency of its occurrence. This is one of the reasons why physicians prescribe more abortive drugs as these medications work best when taken during the initial stages of migraine development. These factors are said to drive the market share during the forecast period from 2019 to 2026.

In North America, the United States alone comprises of around 37 million migration population that accounts for nearly 65% of the worldwide populace. This migraine population is said to increase at a constant pace and contribute to market growth. Also, the territorial market will benefit to a greater extent due to the dispatch of calcitonin gene-related peptide-based treatments                                                                                          

Companies such as Amgen Inc, Eli Lilly, and Company, Novartis International AG, Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd, Allergan plc, etc. are witnessing a shift in terms of strong R&D with the introduction of CGRP-based therapies like ubrogepant and atogepant.

The Migraine Drug Market Outlook 2019-2026, from Optima Insights, will offer a thorough insight on the market growth till the forecast year 2026 based on the market segmentation (Type, Process, End-Use, and Region). The report also comprises comprehensive profiling of companies involved in Migraine Drug, product information, and pipeline information.

The Report Provides Key Insights on

History of the Migraine Drug Market, 2015 to 2017

Forecast of the Migraine Drug Market Growth till the year 2026

The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Migraine Drug Market

Analysis of potential growth segments which will drive the market

Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market

Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics

Request for sample pages @ https://www.optimainsights.org/sample-request/162-migraine-drugs-market

Migraine Drugs Market Based on Route of Administration (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Injectables

Oral

Migraine Drugs Market Based on Therapeutic Class (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Triptans

Ergot

NSAIDs

CGRP antagonists and antibodies

Migraine Drugs Market Based on Treatment Class (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Abortive

Prophylactic

Migraine Drugs Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

North America

Europe

APAC

LAMEA

Migraine Drugs Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)

Eli Lilly and Company

Teva Pharmaceutical Industries Ltd

Novartis AG

Amgen

Allergan plc

Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/162-migraine-drugs-market

About Us

Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.

Contact

Optima Insights

Mr Chucks G

+91 966 6620 365 (Asia) | +1 424 2554 365 (US)

Email: info@optimainsights.org

https://www.optimainsights.org

[healthcareinputs]

Migraine Drugs Market trends and Growth Opportunities

[healthcareinputs]

ADHD Treatment Market is Estimated to Reach $24 bn by 2026

[healthcareinputs]

ADHD Treatment Market Size & Shares, Strategies and Forecast 2026

The Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market was valued at around US$15 billion at the end of 2018. The revenue is said to engross over US$24 billion by 2026, with a CAGR of 6.1%.

ADHD, classified under the diagnostic criteria DSM-5 by the American Psychiatric Association (APA), characterized by patterns of hyperactivity, inattentions, and impulsivity. The worldwide prevalence of ADHD in children was around 2.3% and 2.8% among adults, in 2018. The reported cases of ADHD in the US alone was around 8.1% in children and 5.2% among adults, in 2017, followed by the European Union nations. With around 68 therapeutic options in active development, product launches and more investment in research and development is set to contribute to the market growth through the forecast period 2019-2026.

Continuous rise in the adult ADHD population with many yet to be diagnosed and the policies drafted at the national level are set to drive the market a CAGR of 6.1% throughout the forecast period. For example, the US government conducts national-level surveys assess ADHD population with the help of the Centre for Diseases Control (CDC) which also assesses the ADHD treatment medications covered by state-sponsored insurance or through Medicaid. In 2016, The US government allocated funds of more than US$50 million to address the treatment requirements of individuals with psychological disorders. Similarly, the National Health Services (NHS), UK allocated US$1.2 billion owing to set-up a five-year plan for aiding patients suffering from mental illnesses.

During recent times, increasing awareness of mental illness is on the rise among the global population with more focus on infants and adolescent population. Parents are ready to go the extra mile to groom their children and provide comfort to raise their children without any psychological problems. This is set to boost the market growth during the forecast period from 2019 to 2026.

However, lack of accurate biomarkers for diagnosing ADHD and unknown genetic causes are still grey areas which have to be addressed. Due to this, the cost of diagnosis is also on the higher side. Besides, the cost of treatment is also likely to hamper the market growth. With more investment contribution towards R&D for developing towards improved and accurate diagnostic methodologies should drive the market during the upcoming years.

The ADHD Treatment Market Outlook 2019-2026, from Optima Insights, will offer a thorough insight on the market growth till the forecast year 2026 based on the market segmentation (Drug Class, Age, Distribution Channel, and Region). The report comprises comprehensive profiling of companies involved in drug development, products of ADHD and pipeline information (inclusive of clinical trial data).

The drug class which is used for ADHD can be classified as Stimulants and Non-stimulants. Stimulants include Lisdexamfetamine dimesylate, Dexmethylphenidate, Dextroamphetamine, Methylphenidate, and Amphetamine. While the non-stimulant types are Clonidine, Bupropion, Atomoxetine, and Guanfacine.

Stimulant drugs dominated the market share in the year 2018. The stimulant drugs always have an upper hand over the non-stimulant drugs attributing to more efficacy. For example, Shire’s Lisdexamfetamine ruled the ADHD drug sales in the year 2013 and had also demonstrated to be a gold standard comparable to the other drug lines. Owing to its efficacy, the prescription of stimulant drugs for treating ADHD is increasing. In the year 2018 alone, the usage of the stimulant drug among young ADHD patients was more than 1.56 million, while the adult ADHD individuals taking stimulant drugs were more than 4 million. Recently, the FDA approved Adhansia XR, a high dose (60mg) drug of Purdue Pharma for treating ADHD in children of around 6 years. With more clinical trials underway and govt. support for the usage of stimulant drugs is driving the stimulant ADHD drug market.

However, the lack of evidence on long-term usage of stimulant drugs for ADHD treatment is still debatable. Whereas, non-stimulants are growing in popularity among the US & European populace due to its long-lasting effect and considerably low-risk element. Also, the investments to boost the non-stimulant drug therapies are increasing which is said to drive the drug market in equivalence to the stimulant drug therapies.

The awareness of ADHD is accompanying with frequent clinical visits and physician consults increasing prescription drugs where retails pharmaceutical outlets play a pivotal role and is driving the segment over hospitals segment. This is due to the fact, that hospital inpatient is less owing to lengthy treatment regimens. Thus, making the patients rely on the pharmacies.

Especially, in the US, the amount of prescriptions is more and is increasing every year. Also, the number of ADHD patients in the US are high in number contributing to the North American regional market growth. The North American region is also experiencing the rise of new market entrants because of more investment in R&D and focus on developing therapies that could contribute to improving the lifestyle of the ADHD patient. Following North America, European Market is also said to contribute to the market share. Both North America and US medical coverage policies also contribute to the market share when compared to the other regions such as APAC and LAMEA, which are considered emerging markets with awareness yet to be created.

There are 16 Key Major Players including Pfizer, Prude Pharma L.P, Novartis, Janssen Pharma, Takeda, Sunovion, Tris Pharma, etc. Also, there are 14 companies which are classified as New Market Entrants and Emerging Companies.

Download Sample Report @ https://www.optimainsights.org/sample-request/142-attention-deficit-hyperactivity-disorder-treatment-market

Key Developments:

In May 2019, FDA approved the Monarch eTNS System for ADHD treatment in children aged 7-12 yrs which will be commercialized by NeuroSigma, Inc.,

In June 2019, Researchers from Tehran University confirmed that saffron capsules offer the same effect as methylphenidate on ADHD.

In June 2019, Ironshore Pharmaceutical’s DELEXIS® (novel drug delivery system) based JORNAY PM TM (methylphenidate HCl) extended-release capsule was launched in the US.

In June 2019, Haifa-based InnoSphere’s patented medical “cap” provides promising results for ADHD treatment. The device is said to hit the market by 2022.

The Report Provides Key Insights on

History of the ADHD Treatment Market, 2015 to 2017

Forecast of the ADHD Treatment Market Growth till the year 2026

The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the ADHD Treatment Market

Analysis of potential growth segments which will drive the market

Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market

Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics

Any Questions Ask @ https://www.optimainsights.org/any-question/142-attention-deficit-hyperactivity-disorder-treatment-market

Attention Deficit Hyperactivity Disorder (ADHD) Market Based on Drug Type (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Non-Stimulants

Stimulants

Clonidine (Kapvay)

Guanfacine (Intuniv)

Bupropion

Atomoxetine (Strattera)

Lisdexamfetamine dimesylate (Vyvanse)

Dexmethylphenidate

Dextroamphetamine (Dexedrine, ProCentra, Zenzedi)

Methylphenidate (Concerta, Daytrana)

Amphetamine (Adzenys XR ODT, Evekeo)

Attention Deficit Hyperactivity Disorder (ADHD) Market Based on Age Group (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Adult

Pediatric and neonates

Attention Deficit Hyperactivity Disorder (ADHD) Market Based on Distribution Channel (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

E-commerce

Retail Pharmacies

Hospital Pharmacies

Specialty Clinics

Attention Deficit Hyperactivity Disorder (ADHD) Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

North America

Europe

APAC

LAMEA

Attention Deficit Hyperactivity Disorder (ADHD) Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)

Eli Lilly and Company

Pfizer Inc

Novartis AG

Takeda Pharmaceutical Company Ltd

Tris Pharma

Taisho Pharma

NEOS Therapeutics Inc

Noven Pharmaceuticals

Prude Pharma L.P

About Us

Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.

Contact

Optima Insights

Mr Chucks G

+91 966 6620 365 (Asia) | +1 424 2554 365 (US)

Email: info@optimainsights.org

https://www.optimainsights.org

[healthcareinputs]

Probiotics Market Challenges, Key Players, Opportunities, Forecast Report 2026

Probiotics are defined as live microbial food ingredients that have a beneficial effect on human health. Probiotics are different from other types of bacteria in that they are considered good bacteria or non-pathogenic in healthy people. Moreover, it is a microbial organism which is not harmful which is driving the market growth. The overall Global Probiotics Market was valued at $ 43.13 bn in 2018 and is forecast to grow at a strong 6.75% CAGR between 2018 and 2026, resulting in 2026 global sales of $72.74bn. However, staggering R&D costs for developing new probiotic strains are restraining the market growth. Moreover, prohibition on the use of Antibiotic Growth Promoters (AGPS) in Feed in the EU provide sample opportunity for market Global Probiotics: Key Segments

Product: – Amongst Types & Product, Probiotic Food & Beverages segment captured the largest market share of the global market due probiotics constitute a constantly growing multi-billion-dollar industry and are one of the most commonly consumed food & beverages supplements worldwide. Foods such as yogurt, cheese, ice cream, snacks and nutrition bars, breakfast cereals and infant formulas are supplemented with probiotics.

Ingredient: – Amongst Ingredient, Yeast segment captured the largest market share of the global market due to Yeasts, as an inevitable part of the microflora of various fermented foods and beverages, are found in a wide range of foods from plant or animal origin, where they have a significant impact on food safety and organoleptic properties.

Distribution Channel: Amongst Distribution Channel, EGFR segment captured the largest market share of the global market due to Functional dairy and fortified juices witnessed an increased demand among the supermarkets/hypermarkets. Supermarkets/hypermarkets offer shoppers a one-stop shopping experience in a wide range of products of different brands, enabling them to make an easy purchase. Supermarkets are considered to be the best platform for the launch of new products, particularly the food and beverage segment. It has been observed that new product launches increase the demand for probiotic in supermarkets/hypermarkets. Continuous growth in demand globally is boosting the purchase of probiotics in this retail mode.

Function: Amongst Function, Preventive Healthcare segment captured the largest market share of the global market due to probiotics have the potential to affect health and disease far beyond the gut. There is increasing evidence that probiotics have beneficial effects in preventing a wide range of conditions and improving health.

End-User: Amongst End User, Animal Probiotics segment captured the largest market share of the global market due to the prohibition on manufactured antimicrobial growth promoters (AGP’s) in Europe is a factor driving the probiotics showcase. The intention behind the boycott was to check the act of utilizing anti-infection agents, antimicrobials, and different medications for advancing the development of animals and expanding the generation of meat, milk, and different products.

Region Type: – Probiotics market covers North America, Europe, Asia Pacific and the Rest of the world. North America region dominated the Probiotics market due to massive open doors for animal probiotic products, as governments are becoming progressively worried about the health and productivity of ranch animals. Health deterioration in animals because of the utilization of AGPs has additionally urged domesticated animals owners to utilize probiotic-based feed. The use of probiotics is evaluated to increment at a quick pace in the Asia Pacific, because of the rising consumer request.

Request for sample pages @ https://www.optimainsights.org/sample-request/157-probiotics-market

Key Market Drivers: – Global Probiotics Market Trends

Rising Probiotics in Poultry Nutrition:  Poultry is the cheapest source of animal protein, contributing significantly to supplying the growing demand for animal food products around the world. The consumption and trade in poultry products are increasing rapidly as the human population increases, making it the second-largest source of meat after pork. Probiotics can improve broiler chicken growth rates and control or prevent enteric diseases, including; salmonellosis.

Global Probiotics Market: Restraint

Rising investment in R&D: Significant rise in health concerns to a great extent supplements the market growth in emerging nations such as China and India. These days, organizations have built up their very own R&D centers to take into account the necessities of the business and accordingly stay competitive in the market. In the future, staggering investment in R&D activities is expected to improve the nature of the probiotic products.

Global Probiotics Market: Opportunities and Challenges

Rising health concerns: Current, most individuals experience the ill effects of vaginal infection, gastrointestinal infections, digestive problems, obesity problems, and others. With this feature in thought, major companies working in this market are creating probiotic products that aid them to cure such types of diseases. The impact of developing health concern is moderate in the probiotics market, and its effect is relied upon to increase in the near future.

Lack of awareness among consumers: As of now, the familiarity with probiotics items among buyers is low, is a challenge for market growth. But conferences by the International Food Information Council (IFIC) functional food fact sheets and several publications are expected to make awareness regarding their benefits.

Probiotics Market Based on Product (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Probiotic Dietary Supplements

Probiotic Food & Beverages

Probiotics Market Based on Ingredient (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Bacteria

Yeast

Probiotics Market Based on Distribution Channel (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Hypermarkets/Supermarkets

Pharmacies/Drugstores

Specialty Stores

Online Sales

Probiotics Market Based on Function (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Regular Use

Preventive Healthcare

Therapeutics

Probiotics Market Based on End User (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Human Probiotics

Animal Probiotics

Probiotics Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

North America

Europe

APAC

LAMEA

Probiotics Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)

Arla Foods, Inc

BioGaia AB

Danone

Danisco A/S

Nestle S.A

Yakult Honsha Co., Ltd

Sanofi-Aventis

Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/157-probiotics-market

About Us

Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.

Contact Optima Insights Mr Chucks G +91 966 6620 365 (Asia) | +1 424 2554 365 (US) Email: chuksg@optimainsights.org

[healthcareinputs]

Orthotic Device Market: Growth, Demand and Future Market Predication 2026

Orthotics can be characterized as the brace, support or splint used to align, prevent, support or to address the working of versatile body parts, for example, knee, wrist, shoulder, neck and so on. The medical field which manages the design and assembling of these devices is known as Orthotics. The orthotic devices are fundamentally used to defeat from the disabling illness, congenital condition or traumatic injury. The Overall Global Orthotic Devices Market is expected to grow at a significant compound CAGR rate of 5.25% from USD 3.85 billion in 2018 to USD 6.02 billion in 2026. This expansion in Orthotic Devices is due to a rising focus on improving quality of life and increasing awareness towards orthopedic ailments. However, relatively expensive of custom-made orthotic devices are restraining the market growth. Moreover, inventions in manufacture and modeling technologies are providing ample opportunities for the market.

Global Orthotic Devices: Key Segments

By Product: - Among all Products, Upper Extremity Braces and Support segment occupied the largest market share, owing to the Based on Upper Extremity Braces and Support segment which is sub-categorized into Upper-limb orthoses it is used regularly on patients who have had neuromuscular problems and neurological, musculoskeletal disorders such as peripheral nerve injury, muscle weaknesses, spinal cord injury, cerebral palsy, multiple sclerosis, traumatic brain injury, and stroke.

By Application: - Among all Applications, Neuromuscular and Musculoskeletal Disorders segment occupied the largest market share. Neuromuscular and musculoskeletal problems in instrumental musicians. Among musculoskeletal disorders, regional muscle pain syndromes, particularly of the upper limb, upper trunk, and neck, were most common. Specific entities such as tendinitis and ligament sprain were less common.

By Distribution Channel: - Among all Distribution Channel, Orthotic Clinics segment occupied the largest market share due to Orthotics Clinic is staffed by a team of professionals including Certified Orthotists and Orthotic Technicians. Moreover, the orthotists on staff have specialized experience treating complex pediatric cases that require unique solutions. Fabrication and adjustments of orthoses are done on-site with up-to-date equipment and materials. Our orthotists also provide post-operative casting for orthoses in the operating room.

By Region: - Orthotic Devices market covers North America, Europe, Asia Pacific and the Rest of the world. The Asia Pacific occupied the largest market share due to rising occurrence of traumatic injuries owing to violence, accidents, sports, etc., e-tailors promoting the business of orthotic devices and stable rise in per capita income.

Request for sample pages @ https://www.optimainsights.org/sample-request/128-orthotic-devices-market

Key Market Drivers: -

Global Orthotic Devices Market Trends

The launch of smart socks:  

 The launch of smart socks called smart Moore balance brace which will track the motion, stride length, cadence and gait that physical therapists can analyze the condition and track the recovery by sending the text messages and voice feedbacks to the patient through the mobile app. By using these smart socks patients do not have to spend a lot of time in hospitals consulting the physicians.

Global Orthotic Devices Market: Restraints

The higher cost of custom-made     orthotic devices:

 The higher cost of custom-made orthotic devices is one of the most prominent factors offsetting the growth of the orthotic devices market. Although custom-made orthotic devices have many advantages over the pre-fabricated devices, pre-fabricated devices are widely used owing to affordability and easy availability. The prefabricated devices available in the market presently are technologically advanced and are available in various ranges and sizes used to treat different disorders or diseases.

Global Orthotic Devices Market: Opportunities and Challenges

Development to cure the spinal cord     injury

 This procedure uses continues electric current at different frequencies to stimulate the spinal cord to reawaken its neural processes. It works by implanting a simulator into spinal cord which can be turned on or off according to the patient's requirements via remote. When the stimulator is on the ongoing electric stimulation connects the brain impulse and allows the person to sit with support or stand using a walker.

Poor reimbursement policy:

 Poor healthcare reimbursement and payment models on orthotics are challenging the growth of the market.

 Orthotic Devices Market Based on Product (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Upper Extremity Braces and Support

Lower Extremity Orthotics

Orthotic Splints

 Orthotic Devices Market Based on Application (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Fractures

Neuromuscular and Musculoskeletal     Disorders

Sports Injuries

 Orthotic Devices Market Based on Distribution Channel (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Hospital Pharmacies

Online Pharmacies

Orthotic Clinics

 Orthotic devises Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

North America

Europe

APAC

LAMEA

 Orthotic Devices Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)

Stryker Corporation

Smith & Nephew Plc

Ossur Global

DePuy Synthes

DJO Global, Inc.

Hanger, Inc

Basko Healthcare

Bauerfeind AG

Breg, Inc.

BSN Medical

Freedom Innovations

Fillauer LLC

Conmed Corporation

Acor Orthopaedic Inc

Ascent Meditech Limited

Thuasne

Others

 Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/128-orthotic-devices-market

About Us

Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global Orthotic Devices and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to take better business decisions towards attaining market leadership.

 Contact

Optima Insights

Mr Chucks G

+91 966 6620 365 (Asia) | +1 424 2554 365 (US)

Email: chuksg@optimainsights.org

https://www.optimainsights.org 

[healthcareinputs]

Hybrid Operating Room Market Outlook and Detailed Forecast During 2017 – 2025

Hybrid Operating Room (OR) was initially designed to fuse percutaneous coronary interventions (PCIs) and stent implantations with minimally invasive coronary artery bypass grafting (CABG) strategies. Moreover, this hybrid operating room (OR) is a substitute for conventional operating room outfitted with dynamic medicinal imaging frameworks and devices supporting more high-quality interventional imaging & insignificantly invasive surgeries. The Overall Global Hybrid Operating Room Market is expected to grow at a significant compound CAGR rate of 12.29% from USD 648 million in 2017 to USD 1637 million in 2025. This expansion in the Hybrid Operating Room is due to the rising adoption of minimally invasive surgeries and increasing patient preference for affordable & effective surgical treatments are the factors impacting market growth. However, procedural risks related to the hybrid operating room is hampering market growth. In addition, the growing adoption of robot-assisted surgeries are the factors providing ample opportunities in the market.

Global Hybrid Operating Room: Key Segments

Component: - Among all Component, intraoperative diagnostic imaging systems captured for largest due they are wider application in the cardiovascular, and neurosurgery and additionally, huge minimally invasive surgeries would additionally improve the application of diagnostic devices. In this imaging systems are some of the factors like growing connection of hybrid operating rooms crosswise in important countries, most of the installation costs are related to diagnostic imaging products, continuing integration & automation of operating room workflows, and continuous technical developments in the field of diagnostic imaging.

Application: - Among all application, therapeutic captured for largest due to the rising occurrence of cardiovascular diseases, globally and growing preference of cardiac surgeons for hybrid operating rooms settings through target surgical procedures and this procedure potentially leads to the reduction of complexity, cardiopulmonary bypass time, risk, and to improved outcomes.

End-user: - Among all End User, Hospitals and Surgical Centers captured for largest due to the effective disease managing and owing to a number of diagnostic, and surgical procedures carried out at hospitals and also growing a number of patient emphasis on timely. These hospitals and surgical centers are focusing on an effort to build up these poor outcomes and accommodate surgeon, and interventionist needs, many hospitals have realized typically an OR with a fixed C-arm angiographic system.

Region: - Hybrid Operating Room Market covers North America, Europe, Asia Pacific and the Rest of the world. Asia Pacific region is dominated for the market is the largest share due to incidences of tremendous chances and constantly rising interest advanced in the operating rooms. In this region, it had started various initiatives to instruct people and surgeons about the hybrid room and countries like China and India, are likely to support the adoption of advanced surgical & diagnostic technologies in their respective healthcare systems.

Request for sample pages @ https://www.optimainsights.org/sample-request/61-hybrid-operating-rooms-market

Key Market Drivers: -

Global Hybrid Operating Room Market Trends

Rising adoption of minimally invasive     surgeries:              

 Minimally invasive surgery is rising owing to continues play of an important role in general surgery as an alternative to traditional open surgery as well as traditional laparoscopic techniques and this surgery that includes natural orifice transluminal endoscopic surgery and single-incision laparoscopic surgery (SILS), is ss invasive and has better cosmetic results.

Global Hybrid Operating Room Market: Restraints

Procedural risks related to the hybrid     operating room:

 The related risks faced by the OR is like health-threat posing harms and risks to the health of medicinal services specialists utilized in the hybrid OR are characterized as ergonomic, biochemical, psychological, biological and physical. So, probably harms and risks in the hybrid OR should be defined and fundamental safeguards should be taken, and also should be inspected periodically and necessary training should be given to the healthcare specialists workers.              

Global Hybrid Operating Room Market: Opportunities and Challenges

Growing Adoption of Robot-Assisted Surgeries:

 Robots are helped in surgeries which are united with computer science has been able to augment the surgeon's skills to achieve greatly improved accuracy and precision in complex surgery. The robotic assist surgery tests that have been achieved in a weightless environment and in spite of that it continued appealing to health care organizations and surgeons with a passion for cutting-edge technology. Constantly improving technology in optics, and computer science has introduced virtual reality (VR) and three-dimensional (3D) to operating rooms.

Implementation Time

 Timeline from the initial decision to build a hybrid OR to the completion of the project will depend on whether an existing space is being retrofitted or if it is a new construction project. A carefully planned project that includes bringing together key stakeholders and trusted vendors early in the project can significantly shorten the time and reduce the risk along the way. Making vendor and design decisions up front will assist in the organization and success of the project.

Hybrid Operating Room Market Based on Component (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Audiovisual Display Systems and Tools

Operating Room Fixtures

Surgical Instruments

Other Components

 Hybrid Operating Room Market Based on Application (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Diagnostic

Therapeutic

Biopsy

 Hybrid Operating Room Market Based on End-user (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

Ambulatory Surgical Centers

Hospitals and Surgical Centers

 Hybrid Operating Room Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

North America

Asia-Pacific

Europe

LAMEA

 Hybrid Operating Room Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)

Nuvo Pharmaceuticals Inc

Skytron LLC

Toshiba Corporation

Mizuho Corporation

Alvo Medical

Koninklijke Philips N.V.

Trumpf Medical

Getinge AB

Steris PLC

Stryker Corporation

Siemens AG

 Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/61-hybrid-operating-rooms-market

About Us

Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global Hybrid Operating Room and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to take better business decisions towards attaining market leadership.

Contact

Optima Insights

Mr Chucks G

+91 966 6620 365 (Asia) | +1 424 2554 365 (US)

Email: chuksg@optimainsights.org

https://www.optimainsights.org 

[healthcareinputs]

Neurodegenerative Disease Market Business Growth Analysis with Top Key Players -2026

Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration and/or death of nerve cells. This causes problems with movement (Ataxia), or mental functioning (dementia). The overall Global Neurodegenerative Disease Market is expected to grow at a significant compound CAGR rate of 6.8% from USD 32.65 billion in 2018 to USD 55.26 billion in 2026. This expansion in neurodegenerative disease is due to the ascending public awareness and robust product pipeline for neurodegenerative disease treatment. However, strict regulatory guidelines are restricting market growth. Moreover, increasing occurrence of neurological disorders is providing ample of opportunities.

Global Neurodegenerative Disease: Key Segments

By Indications: - Amongst indications, Alzheimer’s disease segment captured the largest market share of the global market due to Alzheimer's disease (AD) is the most widely neurodegenerative disease. This cause of dementia representing generally 50% everything being equal and in the old and is portrayed by the continuous loss of cognitive functions. Hallmark pathohistological findings of AD include widespread neuronal degeneration, extracellular amyloid plaques and intracellular neurofibrillary tangles (NFT) different lines of evidence indicate that AD grows primarily as the result of an amyloid cascade.

By Drug class: - Amongst Drug class, SSRIs segment captured the largest market share of the global market due to Sertraline (Zoloft) is a particular serotonin reuptake inhibitor (SSRI) that is generally prescribed as an antidepressant and proposed as a potential first-line medication to treat individuals with major depression. SSRIs work by improving the capacity of nerve cells in the brain that regulate emotion. Information is communicated between your brain cells with signals. The chemical messengers that deliver these signals are called neurotransmitters. Such as, sertraline was recently informed to inhibit several types of Na+ and K+ channels

By Region: - Neurodegenerative Disease market covers North America, Europe, Asia Pacific and the Rest of the world. North America region dominated the Neurodegenerative Disease market owing to the development of medical infrastructure and half of the world’s procedures being done in the U.S. because of high medical reimbursement facilities and technological advancement. This region is significant for Parkinson's drugs market. As many as one million Americans live with Parkinson's disease (PD), which is joined the number of individuals people diagnosed to have numerous sclerosis, muscular dystrophy, and Lou Gehrig's disease. It is the second-most common neurodegenerative disorder in the United States. Additionally, there are a large number of patients who go undetected. As the US population keeps on maturing, the quantity of individuals living with Parkinson disease (PD) keeps on developing.

Request for sample pages @ https://www.optimainsights.org/sample-request/106-neurodegenerative-disease-market

Key Market Drivers: -

Global Neurodegenerative Disease Market Trends

·         Robust product pipeline for neurodegenerative disease treatment:

 The major driver for the growth of the Global Neurodegenerative Disease treatment market is a robust pipeline of drugs. For instance, FlorbetapirF 18 sponsored by Avid Radiopharmaceuticals has completed phase 2 clinical trials in 2017. This drug is used as biomarkers for neurodegenerative diseases such as Alzheimer’s disease. F 18 T807 sponsored by Washington school of medicine is in phase 2 clinical trials since 2015. This drug is used to treat Amyotrophic Lateral Sclerosis (ALS).

Global Neurodegenerative Disease Market: Restraints

·         The high Failure rate of Neurodegenerative drugs in clinical trials:

 Thus, there is a need for a greater and more detailed knowledge of the genetic basis and molecular pathology of neurodegenerative diseases. However, this must be matched by better clinical evaluation and understanding of the prodrome and evolution of these diseases and how to detect a meaningful change in clinical trials that can reflect successful modification of disease progression in a manner and timescale that is attractive to industry.

Global Neurodegenerative Disease Market: Opportunities and Challenges

·         Mergers and acquisitions by market players

 Mergers and acquisitions by market players are expected to provide ample opportunities for Neurodegenerative Disease market growth. For instance, in June 2018, Alexion Pharmaceuticals Inc. merged with Complement Pharma, Netherlands-based biotech company to develop preclinical C-6 complement inhibitor CP010 for neurodegenerative disorders such as Parkinson’s disease and Amyotrophic Lateral Sclerosis (ALS). C6 inhibition prevents the formation of Membrane attack complex (MAC), a complex of terminal complement proteins, which has the potential to treat a variety of central nervous system disorders.

·         Lack of reimbursement policies

 Lack of reimbursement policies provided by the government and hospitals for the treatment of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS) is restraining the growth of the market.

Neurodegenerative Disease Market Based on Drug class (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

·         Dopamine inhibitors

·         NMDA

·         SSRIs

 Neurodegenerative Disease Market Based on Indications (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

·         Huntington disease

·         Alzheimer’s disease

·         Parkinson’s disease

·         Amyotrophic Lateral Sclerosis

 Neurodegenerative Disease Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

·         North America

·         Europe

·         APAC

·         LAMEA

 Neurodegenerative Disease Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)

·         Novartis International AG.

·         Pfizer Inc

·         Merck Serono

·         Biogen Idec

·         Teva Pharmaceutical Industries Ltd

·         UCB

·         Bayer Schering

·         Boehringer Ingelheim GmbH

·         Sanofi S.A.

·         GlaxoSmithKline Plc

·         Others

 Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/106-neurodegenerative-disease-market

About Us

Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to take better business decisions towards attaining market leadership.

Contact

Optima Insights

Mr Chucks G

+91 966 6620 365 (Asia) | +1 424 2554 365 (US)

Email: chuksg@optimainsights.org

https://www.optimainsights.org